Logo Image
Opinion|Videos|March 27, 2025

FDA-Approved Treatments for BCG-Unresponsive NMIBC

Experts briefly discuss 3 new FDA-approved treatments for patients who are unresponsive to bacille Calmette-Guérin (BCG) in the last 5 years—pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec—highlighting how each is administered, and share their impressions of the safety and efficacy of these agents.

Episodes in this series

Video content above is prompted by the following:

  • Three new treatments for patients who are unresponsive to BCG were FDA approved in the last 5 years. Briefly discuss each of the following approved therapies and how are they are administered.
  • Pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene firadenovec
  • What are your impressions of the safety and efficacy of these agents?

Related Content

Latest CME

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies
Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

View more
Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis
Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

View more